...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Multicenter pilot study of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres via hepatic arterial infusion in patients with nonresectable colorectal liver metastases.
【24h】

Multicenter pilot study of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres via hepatic arterial infusion in patients with nonresectable colorectal liver metastases.

机译:对无法切除的结直肠肝转移患者进行5-氟尿嘧啶,亚叶酸,干扰素α-2b和可降解淀粉微球通过肝动脉输注的多中心先导研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: It is necessary to establish therapeutic regimens for patients with nonresectable hepatic metastases of colorectal carcinoma. A new regional chemotherapy regimen was tested in a prospective study in three centers. PATIENTS AND METHODS: An arterial port system was implanted in 95 patients. From January 1994 to March 1999, intra-arterial treatment was applied via the hepatic artery using 450 mg starch microspheres with 5 million IU recombinant interferon-alpha 2B, 500 mg/m2 folinic acid and 600 mg/m2 5-FU body surface for 5 days with a 14-day interval. RESULTS: The tumor response rate was 70%. Median disease progression was 17 months, median survival 24 months. The subgroup analysis shows a significant advantage (p<0.00001) for patients with a liver tumor involvement of <25% and a median survival of 39 months compared to a tumor involvement of 25-50% (24 months) and >50% (14 months). Major toxicity problems were observed in 11%. However, there was no termination of therapy on account of theseproblems. CONCLUSION: Intra-arterial chemotherapy with our new regimen was useful in patients with colorectal liver metastases who had only an intrahepatic tumor burden of <50%.
机译:背景:有必要为大肠癌不可切除的肝转移患者制定治疗方案。在三个中心进行的一项前瞻性研究中测试了一种新的区域化疗方案。患者与方法:95例患者植入了动脉端口系统。从1994年1月至1999年3月,使用450 mg淀粉微球与500万IU重组干扰素α2B,500 mg / m2亚叶酸和600 mg / m2 5-FU体表通过肝动脉进行动脉内治疗5每隔14天的天数。结果:肿瘤缓解率为70%。疾病进展中位数为17个月,中位生存期为24个月。亚组分析显示,肝肿瘤受累率<25%,中位生存期为39个月的患者具有显着优势(p <0.00001),而肿瘤受累率为25-50%(24个月)和> 50%(14)个月)。观察到主要毒性问题的比例为11%。但是,没有因为这些问题而终止治疗。结论:我们的新方案进行动脉内化疗对仅肝内肿瘤负荷<50%的结直肠肝转移患者有用。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号